Bipolar Affective Disorder Current Episode Depression — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for bipolar affective disorder current episode depression. 56 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
56
Active US patents
64/100
Avg vulnerability
$300M
Annual revenue covered

Originators in Bipolar Affective Disorder Current Episode Depression

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Eli Lilly 56 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating bipolar affective disorder current episode depression. Each bar = one year. Y-axis scaled to peak year (36 patents).

36
31
4
32
4
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zyprexa
olanzapine
 Eli Lilly 56 64 $300M 2031-08-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12194035 Zyprexa method of use 81 2031-08-23
12194035 Zyprexa method of use 81 2031-08-23
12194035 Zyprexa method of use 81 2031-08-23
12194035 Zyprexa method of use 81 2031-08-23
11793805 Zyprexa method of use 76 2031-08-23
11351166 Zyprexa method of use 76 2031-08-23
11241425 Zyprexa method of use 76 2031-08-23
11793805 Zyprexa method of use 76 2031-08-23
11793805 Zyprexa method of use 76 2031-08-23
11241425 Zyprexa method of use 76 2031-08-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
11707466 Zyprexa formulation 50 2041-11-12
11707466 Zyprexa formulation 50 2041-11-12
11707466 Zyprexa formulation 50 2041-11-12
11707466 Zyprexa formulation 50 2041-11-12
12390474 Zyprexa formulation 55 2041-11-12
12390474 Zyprexa formulation 55 2041-11-12

Related